The Acquirers Podcast

Eric Jorgenson, author and curator behind The Book of Elon, distills Musk’s public ideas into mentor-like lessons. He breaks down Musk’s focus on speed, first-principles thinking, and attacking bottlenecks. They discuss Musk’s factory-level work ethic, the 2008 do-or-die moment, reusable rockets and launch-cost declines, and rapid changes at Twitter/X after the acquisition.

Tim Travis, founder of T&T Capital and deep value investor, discusses private credit structures and why headlines overstate risks. He contrasts asset managers versus BDCs and explains buying BDCs at wide NAV discounts. Tim covers energy names like Devon and Occidental and highlights MLPs and pipelines for defensive yield. He also walks through cash‑secured puts and option strategies for conservative entries.

Value: After Hours is a podcast about value investing, Fintwit, and all things finance and investment by investors Tobias Carlisle, and Jake Taylor. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Soldier of Fortune: Warren Buffett, Sun Tzu and the Ancient Art of Risk-Taking⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Kindle⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠)We are live every Tuesday at 1.30pm E / 10.30am P.See our latest episodes at https://acquirersmultiple.com/podcastAbout Jake Jake's Twitter: https://twitter.com/farnamjake1Jake's book: The Rebel Allocator https://amzn.to/2sgip3lABOUT THE PODCASTHi, I'm Tobias Carlisle. I launched The Acquirers Podcast to discuss the process of finding undervalued stocks, deep value investing, hedge funds, activism, buyouts, and special situations.We uncover the tactics and strategies for finding good investments, managing risk, dealing with bad luck, and maximizing success.SEE LATEST EPISODEShttps://acquirersmultiple.com/podcast/SEE OUR FREE DEEP VALUE STOCK SCREENER https://acquirersmultiple.com/screener/FOLLOW TOBIASWebsite: https://acquirersmultiple.com/Firm: https://acquirersfunds.com/ Twitter: ttps://twitter.com/GreenbackdLinkedIn: https://www.linkedin.com/in/tobycarlisleFacebook: https://www.facebook.com/tobiascarlisleInstagram: https://www.instagram.com/tobias_carlisleABOUT TOBIAS CARLISLETobias Carlisle is the founder of The Acquirer’s Multiple®, and Acquirers Funds®. He is best known as the author of the #1 new release in Amazon’s Business and Finance The Acquirer’s Multiple: How the Billionaire Contrarians of Deep Value Beat the Market, the Amazon best-sellers Deep Value: Why Activists Investors and Other Contrarians Battle for Control of Losing Corporations (2014) (https://amzn.to/2VwvAGF), Quantitative Value: A Practitioner’s Guide to Automating Intelligent Investment and Eliminating Behavioral Errors (2012) (https://amzn.to/2SDDxrN), and Concentrated Investing: Strategies of the World’s Greatest Concentrated Value Investors (2016) (https://amzn.to/2SEEjVn). He has extensive experience in investment management, business valuation, public company corporate governance, and corporate law.Prior to founding the forerunner to Acquirers Funds in 2010, Tobias was an analyst at an activist hedge fund, general counsel of a company listed on the Australian Stock Exchange, and a corporate advisory lawyer. As a lawyer specializing in mergers and acquisitions he has advised on transactions across a variety of industries in the United States, the United Kingdom, China, Australia, Singapore, Bermuda, Papua New Guinea, New Zealand, and Guam. He is a graduate of the University of Queensland in Australia with degrees in Law (2001) and Business (Management) (1999).

Derek Pilecki, small-cap bank specialist and portfolio manager at Gator Capital, explains why regional banks and non-bank financials look cheap and which franchises survive rising rates. He discusses private credit, yield-curve effects, insurance risks, M&A trends, fintech competition, and how to size long/short positions. Short ideas include complex or structurally weak financials.

Jonathan Tepper, founder of Previt Capital and author of The Myth of Capitalism and Shooting Up, blends investing smarts with a personal memoir. He discusses concentration and record profit margins, why dominant platforms resist disruption, AI’s real threats to sectors, and the backstory behind his memoir and life from Spain to finance. Short, candid, and wide-ranging.

Juan Torres, co-portfolio manager for Emerging Market Equities at Neuberger Berman, explains country-level value investing across EM markets. He discusses valuation dispersion and why the cheapest quintile stays attractive. He covers Taiwan's concentration risk around TSMC, bank balance-sheet checks in EM, currency hedging philosophy, and why price can make any country investable.

Jay Hatfield, founder and portfolio manager at InfraCap focused on monthly income strategies and preferreds. He explains InfraCap’s income-focused ETFs, how preferreds and high-yield instruments supply steady cash, and why short-dated covered calls boost yield without capping upside. He also discusses leverage management, liquidity mechanics, and macro risks that shape income investing.

Stephen Farrington, an independent value investor and Substack writer known as Unemployed Value Degen, discusses niche deep-value ideas. He covers Abacus ($ABX) and the life-settlements business, Newell Brands ($NWL) and its turnaround indicators, and Ramaco Resources ($METC) as a critical-minerals play. Short, focused takes on small-value rotation, manufacturing rebound, and consumer demand follow.

Ian Cassel, microcap investor and founder of MicroCapClub, who led the Planet MicroCap acquisition. He talks about why small caps can deliver outsized returns. Short takes on sectors powering the rally, dilution and IPO trade-offs, position sizing and execution, journaling and investing psychology. Practical notes on using AI for diligence and where cheap opportunities sit now.

Andrew Summers, founder of Summers Value Fund, shares insights from his extensive experience in healthcare and biotech investing. He discusses regulatory complexities impacting the sector, recent underperformance, and the attractiveness of biotech as it matures. Summers highlights the dramatic patent cliffs ahead for large pharmaceutical companies and the role of innovative treatments like GLP-1s. He also explores how technologies like AI are reshaping drug development and why small-cap healthcare offers compelling opportunities.